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Aβ aggregationThe hallmarks of Alzheimer disease are amyloid-β plaques and neuroﬁbrillary tangles accompanied by signs of
neuroinﬂammation. Lysozyme is a major player in the innate immune system and has recently been shown to
prevent the aggregation of amyloid-β1-40 in vitro. In this study we found that patients with Alzheimer disease
have increased lysozyme levels in the cerebrospinal ﬂuid and lysozyme co-localized with amyloid-β in plaques.
In Drosophila neuronal co-expression of lysozyme and amyloid-β1-42 reduced the formation of soluble and insol-
uble amyloid-β species, prolonged survival and improved the activity of amyloid-β1-42 transgenic ﬂies. This
suggests that lysozyme levels rise in Alzheimer disease as a compensatory response to amyloid-β increases
and aggregation. In support of this, in vitro aggregation assays revealed that lysozyme associates with amyloid-
β1-42 and alters its aggregation pathway to counteract the formation of toxic amyloid-β species. Overall, these
studies establish a protective role for lysozyme against amyloid-β associated toxicities and identify increased ly-
sozyme in patients with Alzheimer disease. Therefore, lysozyme has potential as a new biomarker as well as a
therapeutic target for Alzheimer disease.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Alzheimer disease is the primary cause of dementia and is manifest-
ed as an accumulation of oligomers and extracellular plaques composed
of amyloid-β (Aβ), intraneuronal neuroﬁbrillary tangles composed of
hyperphosphorylated tau, synaptic failure and progressive neurodegen-
eration (Blennow et al., 2006). There are several risk factors proposed
for sporadic Alzheimer disease, with ageing and neuroinﬂammation
suggested to be important contributors to the disease (Akiyama et al.,
2000; Heneka and O'Banion, 2007; McGeer and McGeer, 2007). There
is evidence that Aβ deposits in the brain trigger neuroinﬂammation
via activation of the microglia and astrocytes that surround amyloidlar Biotechnology, Department
inköping, Sweden.
gy, Department of Clinical and
Sweden.
rorsson),
ect.com).
. This is an open access article underplaques (Halle et al., 2008; Wyss-Coray and Rogers, 2012). However,
whether inﬂammation is the driving force, a contributor or a secondary
effect of Alzheimer disease pathology is not known. Sequential cleavage
of the amyloid precursor protein (APP) generates Aβ; and the accumu-
lation of Aβ is central to Alzheimer disease pathogenesis (Hardy and
Selkoe, 2002). Several Aβ isoforms are observed, with Aβ1-40, Aβ1-42,
Aβ1-43 and the N-terminally truncated isoforms Aβ3-42 and Aβ11-42
being neurotoxic (Jonson et al., 2015) and Aβ1-42 is the most abundant
isoform during Alzheimer disease and is highly aggregation prone. Dur-
ing Aβ aggregation, monomers turn into oligomers, preﬁbrillar species,
ﬁbrils and insoluble plaques. Aβ aggregation is characterized by a lag
phase in which seeds are formed and a logarithmic phase in which the
seeds elongate into ﬁbrils that catalyze further ﬁbrillization, which in
turn accelerates the aggregation process (Wogulis et al., 2005). In the
Alzheimer disease brain, Aβ1-42 is the main constituent of plaques
(Portelius et al., 2010). Intermediate structures of aggregated Aβ species
generated prior to the formation of the insoluble plaques; oligomers are
cytotoxic and cause phosphorylation of tau, synaptic failure and neuro-
nal death (Lesne et al., 2013). Several endogenous proteins can manip-
ulate the aggregation process of Aβ. The physical interaction betweenthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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macroglobulin can inhibit Aβ aggregation; thus, these chaperones may
play an important role in Alzheimer disease pathogenesis (Matsubara
et al., 1996; Du et al., 1998; Barral et al., 2004; Raman et al., 2005;
Yerbury et al., 2009).
Lysozyme is part of the innate immune system and possesses bacte-
riolytic properties capable of hydrolyzing peptidoglycans in the bacteria
cell wall (Fleming, 1922). Lysozyme is secreted by epithelial cells, mac-
rophages, astrocytes and microglia, and the enzyme is abundant in
various tissues and ﬂuids including liver, spleen, milk, tears, saliva and
CSF (Ganz, 2004). Lysozyme retains both anti-oxidant and anti-
inﬂammatory properties (Ogundele, 1998; Liu et al., 2006; Lee et al.,
2009), and the level of lysozyme has been reported to be increased in
CSF during inﬂammation (Hällgren andVenge, 1982). Lysozymewas re-
cently shown to inhibit Aβ1-40 aggregation via binding to themonomer-
ic form of Aβ1-40 (Luo et al., 2013; Luo et al., 2014) and has also been
predicted to prevent the aggregation of Aβ17-42 via binding to mono-
meric Aβ species (Das et al., 2014). Moreover, in a recent largemicroar-
ray investigation of more than 12,500 genes in ﬁve Alzheimer mouse
models lysozyme together with e.g. TREM2 were some of the key im-
mune genes identiﬁed to be overexpressed (Matarin et al., 2015).
In this study we investigated whether lysozyme is activated in
Alzheimer disease. Using Alzheimer disease patient samples, we discov-
ered that the level of lysozyme was signiﬁcantly increased in the CSF
and that lysozyme co-localized with Aβ1-42 in plaques. In a Drosophila
model of Aβ1-42 toxicity, lysozyme co-expression reduced Aβ1-42 levels,
extended survival and improved the activity of the ﬂies. Using aggrega-
tion assays we revealed that lysozyme binds with Aβ1-42 inhibiting its
aggregation, and in neuronal cultures this has a neuroprotective role.
Our results provide evidence that lysozyme is activated in Alzheimer
disease, and therefore has potential as a biomarker. Its role appears to
be neuroprotective for increasing Aβ toxicity identifying a potential
new therapeutic pathway for the disease.
2. Materials and methods
2.1. Human study populations
2.1.1. CSF cohorts and lysozyme measurements
This study was performed on two separate sets of de-identiﬁed,
archived matched CSF and serum samples. The study was approved
by the Ethical committee at the University of Gothenburg. All samples
were provided by the Clinical Neurochemistry Laboratory, Sahlgrenska
University Hospital/Mölndal, Sweden. The samples were collected
from patients who sought medical advice because of minor cognitive
or neurological symptoms. Following routine clinical assessment, the
CSF biomarkers for Alzheimer's disease; P-tau181P, T-tau and Aβ1–42
(Hansson et al., 2006) were analyzed in these patients, and based
on their neurochemical proﬁle, the samples were divided into
three groups; those with CSF biomarkers in the Alzheimer's disease
range (AD, n = 10), those with CSF biomarkers in the control range
(C, n=10) and thosewith CSF biomarkers indicative of neuronal injury
but not Alzheimer's disease (having high T-tau, n = 5). The samples
with Alzheimer's disease were designated according to CSF biomarker
levels using cutoffs that have 95% sensitivity and 80% speciﬁcity, includ-
ing T-tau 350 ng/l, Aβ1–42 530 ng/l and P-tau181P 60 ng/l (Hansson et al.,
2006). For further description of patient information, CSF collection and
protein analysis via ELISA and Western blotting, see the previously de-
scribed methods (Armstrong et al., 2014). The primary antibodies
used for Western blotting were lysozyme (A0099, Dako, Glostrup,
Denmark) and GAPDH (247 002, Synaptic Systems GmbH, Göttingen,
Germany). Equal sample loading was veriﬁed by Ponceau S (Sigma-Al-
drich, St. Louis, MO, USA) staining of total protein in each lane on the
membranes. The ﬁlms were scanned and the immunoblots were quan-
tiﬁed using the Image J program (available at http://rsbweb.nih.gov/ij/).
The relative amount of protein corresponding to an immunoreactiveband was calculated as a product of average optical density of the area
of the band.
2.1.2. Autopsy conﬁrmed cohorts with brain samples and tissue localization
methods
Tissues were received from the Sydney Brain Bank at Neuroscience
Research Australia and the New South Wales Tissue Resource Centre
at the University of Sydney which are supported by the National Health
andMedical Research Council of Australia (NHMRC), University of New
South Wales, Neuroscience Research Australia, Schizophrenia Research
Institute and National Institute of Alcohol Abuse and Alcoholism (NIH
(NIAAA) R24AA012725). Brain tissue collection procedures were ap-
proved by the University of New South Wales Human Research Ethics
Committee and informed consent was obtained from all individuals
prior to donation of their brain. Caseswere selected based on their char-
acterization with Alzheimer disease according to established neuro-
pathological criteria (Montine et al., 2012).
For immunohistochemistry, formalin-ﬁxed, parafﬁn-embedded
10 μm sections of inferior temporal cortex tissues underwent heat-
induced antigen retrievalwith citrate buffer (pH6.0) for 3min, followed
by formic acid pretreatment for 3 min. Then, sections were sequentially
double-labeled with rabbit monoclonal anti-human lysozyme (1:100,
Abcam, Cambridge, UK) visualized with the NovoLink Polymer Detec-
tion System (RE7150-K, Leica Biosystems, Wetzlar, Germany). Double
labeling was performed with the lysosome antibody and mouse mono-
clonal anti-human Aβ1–42 (1:200, M0872, Dako, Glostrup, Denmark) vi-
sualized with donkey anti-rabbit Alexa Fluor 568 (1:250, A-10,042,
Molecular Probes, Waltham, MA, USA) and goat anti-mouse Alexa
Fluor® 488 (1:500, A-11,001, Molecular Probes, Waltham, MA, USA)
respectively. Sections were coverslipped with VectaShield for ﬂuores-
cence (H-1000, Vector, Burlingame, CA, USA) and examined on a confo-
cal ﬂuorescence microscope (Nikon C1si). Control experiments for the
double labeling were performed with only a single or no primary anti-
body with the result of single or no protein labeling observed.
2.1.3. Lysozyme detection by Mesoscale Discovery (MSD)
The MSD technique is similar to the ELISA technique but with
electrochemiluminescent detection of the analytes. A standard binding
96-well multi-array plate (L15XA-6, MSD) was coated with 25 μl of
15 μg/ml cAbHuL6 (the N-terminal domain of a camelid heavy-chain
antibody speciﬁc for human lysozyme (Dumoulin et al., 2003) (1 h,
RT), then the plate was washed with 150 μl PBS-T. A total of 25 μl
block solution (1%milk in PBS-T) was added to the wells and incubated
(1 h, RT), then 20 μl CSF was added to the plate and incubated (1 h, RT).
The plate waswashed and 25 μl rabbit anti-human lysozyme antiserum
(1:1000 in 1%milk in PBS-T)was added to thewells and incubated (1 h,
RT). The platewaswashed, and 25 μl Sulfo-Tag goat anti-rabbit antibody
(R32AB-5,MSD, 1:500 in 1%milk in PBS-T)was added and the platewas
incubated (1 h, RT). The plate was washed, and 150 μl 2X read buffer
(R92TC-2, MSD)was added. The platewas analyzed using a SECTOR Im-
ager 2400 instrument (MSD).
Ten ﬂy heads of each genotype were snap-frozen, 150 μl PBS-PI (PBS
buffer with Complete EDTA-free Protease Inhibitor Cocktail Tablets,
Roche Diagnostics, Basel, Switzerland) was added and the ﬂy heads
were homogenized. The samples were centrifuged (13,000 rpm,
1 min); the supernatant constituted the soluble fraction. Lysozyme
levels were detected as described above.
2.1.4. Cell culture
Human SH-SY5Y neuroblastoma cells were cultured in Dulbecco's
Modiﬁed Eagle Medium:Nutrient Mixture F-12 GlutaMAX™ supple-
mented with 100 U/ml penicillin, 100 μg/ml streptomycin, 1% MEM
non-essential amino acids solution and 10% fetal bovine serum in a
humidiﬁed atmosphere with 5% CO2. To achieve a neuronal-like pheno-
type, the cells were pre-treated with 10 μM retinoic acid (Sigma-Al-
drich, St. Louis, MO, USA) for 7 days prior to the experiments. Cell
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manufacturer's instructions. The XTT absorbance was measured at
450–750 nmusing a VictorWallac plate reader (PerkinElmer,Waltham,
MA, USA). Human neuroglioma H4APPswe cells were cultured in Opti-
MeMR supplementedwith 100U/ml penicillin, 100 μg/ml streptomycin,
2.5 μg/ml blasticidin, 200 μg/ml hygromycin B and 10% fetal bovine
serum in a humidiﬁed atmosphere with 5% CO2.
2.1.5. Oligomeric Aβ1-42 preparation
Freshly made oligomeric Aβ1–42 was prepared for each experiment.
Recombinant Aβ1–42 (rPeptide)was lyophilized in hexaﬂuoroisopropanol
(HFIP) and dissolved in DMSO to 1.5 mM. Aβ1-42 was vortexed and dilut-
ed with cold HEPES buffer to a concentration of 100 μM, vortexed 30 s,
then sonicated 2 min and incubated 24 h at 4 °C. Size exclusion chroma-
tography and electron microscopy conﬁrmed the formation of oligomers
(Domert et al., 2014).
2.1.6. Fluorescent labeling of lysozyme
The free amineof the lysine on lysozymewas labeled using the Alexa
Fluor® 488 protein labeling kit (Life Technologies). Sodium bicarbonate
buffer (pH 8.5) was used to prevent aggregation during the labeling
process. The labeled proteins were separated from the free dye by gel
chromatography using a PD-10 column eluted with HEPES buffer
at pH 7.4. The concentration of Alexa-488-labeled lysozyme was mea-
sured on a Nanodrop ND-1000 spectrophotometer (Saveen Werner,
Limhamn, Sweden) and calculated by subtracting the contribution of
Alexa-488 at 280 nm from the observed absorbance using the following
equation:
A280 lysozymeð Þ ¼ A280 observedð Þ−A495 Alexa 488ð Þ
ϵ 280 Alexa 488ð Þ
ϵ 495 Alexa 488ð Þ
The concentrationwas calculatedusing the extinction coefﬁcient of ly-
sozyme as 2.64 ml mg−1 cm−1 at 280 nm and the 71,000 cm−1 M−1 M
extinction coefﬁcient of the Alexa 488 ﬂuor probe. The calculated labeling
percentage was ~58%.
2.1.7. Fluorescence resonance energy transfer (FRET) using steady state
ﬂuorescence spectroscopy
The intermolecular interactionbetween lysozyme andAβ specieswas
studied by FRET using steady-state ﬂuorescence spectroscopy. Fluores-
cence emission spectrameasurementswere performed in a Tecan Saﬁre2
multiplate reader (Tecan Group Ltd., Männedorf, Switzerland). Alexa-
488 (Exmax 494 nm and Emmax 520 nm)-labeled lysozyme was used as
the donor and N-terminal TAMRA (carboxytetramethylrhodamine)-
labeled synthetic Aβ1-42 (Innovagen, Lund, Sweden) was used as the ac-
ceptor (Exmax 555 nm and Emmax 580 nm) (Biskup et al., 2007, Koch
et al., 2008). Before the measurements, lysozyme-Alexa-488 (200 nM)
was incubated for 1 h at 37 °C with 8 μM of monomeric Aβ-TAMRA in
HEPES buffer (pH 7.4). Size exclusion chromatography conﬁrmed that
more than 99% of the Aβ-TAMRA was monomers using a Superdex 75
10/300 GL column (GE Healthcare) equilibrated in PBS.
2.1.8. ThT aggregation assay
Recombinant Aβ1-42 (rPeptide) lyophilized from HFIP was dissolved
in 2 mM NaOH to a concentration of 222 μM. Aβ1-42 was diluted to a
ﬁnal concentration of 10 μM and then aggregated alone or with 10 or
40 μM lysozyme (Sigma-Aldrich) in the presence of 0.3 μM ThT. The
samples were loaded in a Corning 96-well black-well clear-bottom mi-
crotiter plate (Corning Inc. Life Sciences, Tewksbury, MA, USA), and the
in situ change in ThT ﬂuorescence was recorded under quiescent condi-
tions at 37 °C for 24 h using ﬂuorescence spectroscopy (Tecan). The ex-
citation was performed at 440 nm and the emission intensity were
recorded at 480 nm. For the ThT curves of Aβ aggregated alone or in
the presence of lysozyme (10 μM), the rate of aggregation (k) was ex-
tracted from the maximal slope of the sigmoidal curve and the length
of the lag time (tl) was determined by ﬁtting the initial data to a straightline and a tangent to the steepest region of the growth curve; tl is de-
ﬁned as the time pointwhere the straight line and the tangent intersect.
2.1.9. Transmission electron microscopy (TEM) of end products from the
ThT aggregation assay
Samples collected from the 24 h ThT aggregation assay were snap-
frozen in liquid nitrogen. A total of 10 μl of each sample was added to
formvar/carbon-coated 400 mesh copper transmission electron micro-
scope grids (Agar Scientiﬁc Ltd., Stansted, UK) for 2 min. The ﬂuid was
removed and 10 μl of 4% uranyl acetate was added for 2 min. The grids
were analyzed with a JEOL JEM1230 transmission electron microscope
(JEOL Ltd., Tokyo, Japan) equipped with a SC1000 ORIUS CCD camera
and the DigitalMicrograph (DM) v.1.71.38 software (Gatan Inc., Pleas-
anton, CA, USA).
2.1.10. Immunoanalyses of end products from the ThT aggregation assay
A total of 20 μl of the 24 h product formed in the ThT aggregation
assay was transferred for each reaction. The samples were incubated
for 1 h at RT with an antibody solution containing mouse monoclonal
anti-Aβ antibody (1:500 in PBS; Mabtech, Nacka strand, Sweden) and
rabbit monoclonal anti-lysozyme antibody (1:500 in PBS; Abcam). The
sampleswere centrifuged for 10min at 13,000 rpmand the supernatant
was discarded. The pellet was resuspended in a secondary antibody so-
lution containing ﬂuorescently labeled goat anti-mouse (1:600 in PBS;
Alexa Fluor 594 goat anti-mouse; Life technologies) and ﬂuorescently
labeled goat anti-rabbit (1:600 in PBS; Alexa Fluor 488 goat anti-
rabbit; Life technologies) and incubated for 1 h at RT. The samples
were centrifuged for 10 min at 13,000 rpm and the supernatant was
discarded. A total of 5 μl of the pellet was transferred onto SuperFrost
Plus slides (Menzel-Gläser, Braunschweig, Germany) and allowed to
dry. The slides were mounted using ﬂuorescence mounting medium
(Dako) and analyzed using a Zeiss LSM 780 confocal microscope
(Zeiss, Oberkochen, Germany).
The ELISA analyses of the 24 h endpoint sampleswere performed by
a previously described method that speciﬁcally detects the aggregated
forms of Aβ without detecting monomers (Höltta et al. 2013). The
samemonoclonal anti-Aβ N-terminal speciﬁc 82E1 antibody (IBL Inter-
national, Hamburg, Germany) was used both for capture and detection.
2.1.11. Fly stocks
The Gal4/UAS system was used for CNS-speciﬁc expression of UAS
transgenes in Drosophila melanogaster (Brand and Perrimon, 1993).
The C155-gal4 driver (Lin and Goodman, 1994) was used to express
the transgenes in the CNS. Strains of C155-gal4 ﬂies carrying UAS-
containing genes encoding human wild type lysozyme (Kumita et al.
2012), Aβ1-42 (Crowther et al., 2005) and both lysozyme and Aβ1-42
(both containing a secretion-tag) were generated. Background C155-
gal4 w1118 was used to generate control ﬂies. D. melanogaster stocks
were allowed to develop under a 12:12 h light:dark cycle at 29 °C at
60% humidity. The ﬂies were kept in 50ml plastic vials containing stan-
dard Drosophila food (corn meal, molasses, yeast and agar) and main-
tained post-eclosion in 50 ml plastic vials containing six ml agar (20 g
agar and 20 g sugar dissolved in 1 l water) and yeast paste (dry Baker's
yeast dissolved in water) at 29 °C under 12:12 h light:dark cycle.
2.1.12. Drosophila longevity and locomotor assays
One hundred Drosophila ﬂies of each genotype were divided into
plastic vials containing agar food and yeast paste with ten ﬂies in each
vial and kept at 29 °C in a 12:12 h light:dark cycle. Every 2–3 days the
ﬂies were transferred to fresh food and the numbers of ﬂies alive were
counted. Prism GraphPad software 6 (GraphPad Software, San Diego,
CA USA) was utilized to graph Kaplan-Meier survival curves (Kaplan
and Meier, 1958) and to run the log rank statistical analysis.
To analyze the locomotor behavior of the ﬂies, a locomotor assay
using the iFly software (Jahn et al., 2011), was used. For each genotype,
three vials with ten ﬂies in each were collected and ﬁlmed for 90 s. The
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behavior), yielding three video clips with three clips of 30 s each. The
videos were processed and analyzed using the iFly software, which cal-
culated the velocities and the angle of movement for each clip. The data
were plotted using GraphPad Prism 6.
2.1.13. Immunohistochemistry of ﬂy heads
Drosophila heads were embedded on the day of eclosion or at day 20
in Tissue-Tek OCT compound (Histolab, Gothenburg, Sweden) using
Cryomold specimen molds and stored at −80 °C until use. The OCT
blocks were sectioned using a Microm HM 550 Cryostat (Microm Inter-
national, Walldorf, Germany) into 20 μm thin sections that were placed
on SuperFrost Plus slides (Menzel-Gläser) and stored at−20 °C until
use. The sections were ﬁxed in 4% w/v PFA in PBS for 10 min at RT.
The slides were washed in PBS (3 × 3 min) followed by a (1 × 3 min)
wash in PBS-T (PBS with 0.05% v/v Tween-20) before blocking in 10%
w/v BSA in PBS-T for 1 h at RT. Mouse monoclonal anti-Aβ antibody
(1:500 in 1% BSA w/v in PBS-T; Mabtech) and rabbit monoclonal anti-
lysozyme (1:500 in 1% BSA w/v in PBS-T; Abcam) were added to the
slides and incubated for 1 h at RT. The slides were washed with PBS-T
(3 × 5 min). Goat anti-mouse ﬂuorescently labeled secondary antibody
(1:600 in 1% w/v BSA in PBS-T; Alexa Fluor 594 goat anti-mouse; Life
Technologies) and goat anti-rabbitﬂuorescently labeled secondary anti-
body (1:600 in 1% w/v BSA in PBS-T; Alexa Fluor 488 goat anti-rabbit;
Life Technologies) were applied to the slides and incubated for 1 h at
RT. The slides were mounted using Vectashield with DAPI (Vector Lab-
oratories). The slides were analyzed using a Zeiss LSM 780 confocal mi-
croscope (Zeiss). The micrographs were processed using Adobe
Photoshop (Adobe Systems, San Jose, CA, USA); all images were treated
identically.
2.1.14. Analyses of Aβ1-42 levels in Drosophila
Fiveﬂy heads for each genotypewere placed in Eppendorf tubes and
snap frozen, and then analyzed onMSD as described previously (Caesar
et al., 2012). To adjust for variation in the protein extraction step, a
quantitation of the total amount of protein from each sample of ﬂy ho-
mogenate was performed using the Bio-Rad DC Protein Assay Kit II
(500–0112, Bio-Rad, Hercules, CA, USA).
2.1.15. Lysozyme expression in cells and binding to ﬁbrillar Aβ
Neuroblastoma and neuroglioma cells were incubated with oligo-
meric Aβ1–42 diluted in serum-free culture media at a ﬁnal concentra-
tion of 1 μM for 1 h. After extensive PBS washing and trypsinization,
the cells were re-seeded and grown in serum-free media for 24 orTable 1
Study demographics of Alzheimer disease (AD) patients versus control (C) individuals CSF set 1,
the mean and (range).
Study group Age years Sex
M:F
CSF T-tau ng/l
CSF set 1
AD
n = 10
68.5
(58–89)
5:5 880
(580–1680)
C
n = 10
74
(43–82)
6:4 295
(160–390)
CSF set 2
AD
n = 10
73
(50–89)
4:6 844
(467–1350)
C
n = 10
64
(50–76)
6:4 245
(141–363)
CSF set 3
C 1-5 set 1
n = 5
72
(61–79)
3:2 271
(170–380)
High-T-tau
n = 5
65.2
(26–82)
2:3 2541
(487–9620)48 h. The cells were lysed, and lysozyme levels were measured via
Western blotting as described previously (Armstrong et al., 2014).
A total of 50 μg recombinant Aβ1-42-TAMRA lyophilized from HFIP
was dissolved in 2.2 μL DMSO, diluted to 100 μM in 20 mM HEPES
(pH 7.4), vortexed, and aggregated at 37 °C for 24 h. The aggregated ﬁ-
brillar Aβ1-42-TAMRA was diluted to a ﬁnal concentration of 10 μM and
incubated 1 h at RT alone orwith 40 μM lysozyme-Alexa 488 (Sigma-Al-
drich). The samples were centrifuged for 10 min at 13,000 rpm and the
supernatant was discarded. A total of 5 μl of the pellet was transferred
onto SuperFrost Plus slides (Menzel-Gläser) and allowed to dry. The
slides were mounted using ﬂuorescence mounting medium (Dako)
and sealed with nail Polish and were analyzed using a Zeiss LSM 510
META confocal microscope (Zeiss).
2.2. Statistical analysis
All statistical analyses were performed using GraphPad Prism
Software.
The mean value and standard deviation or standard error of the
mean were calculated for all data. The nonparametric Mann–Whitney
U test was used to test for signiﬁcant differences between groups. For
Drosophila longevity statistics, Kaplan–Meier survival curves and log-
rank (Mantel–Cox) statistical analyses were performed. Statistical sig-
niﬁcance was deﬁned for p-values less than or equal to 0.05 (*), 0.01
(**) and 0.001 (***).
3. Results
3.1. Lysozyme is increased in CSF and present in plaques from patients with
Alzheimer disease
Lysozyme levels were tested in two cohorts of CSF samples collected
from patients with Alzheimer disease and controls (Table 1, CSF set 1
and 2). Lysozyme levels were signiﬁcantly higher in the CSF samples
from Alzheimer patients (Fig. 1A and B). This was demonstrated using
two different methods: Western blotting with quantiﬁcation as shown
in Fig. 1A and theMeso Scale Discovery technique for the second valida-
tion cohort of CSF samples as shown in Fig. 1B. Lysozyme levels did
not differ between the control and Alzheimer disease cohorts in
matched serum samples (Fig. 1B). To investigate whether lysozyme
up-regulation was due to general neurodegeneration, lysozyme levels
were analyzed in the CSF of a third set of non- Alzheimer disease pa-
tients who had normal Aβ1-42 and P-tau181P levels but elevated total
tau (T-tau). No signiﬁcant difference between lysozyme levels wereCSF set 2, and CSF set 3 (C 1-5 from set 1 versus High T-tau patients). Data are presented as
CSF Aβ42 ng/l CSF P-tau181P ng/l CSF/serum
Albumin ratio
330
(310–390)
123
(84–177)
5.5
(4.2–9.5)
780
(553–1140)
42
(26–61)
7.8
(3.8–10.8)
342
(200–440)
97
(76–165)
7.6
(6.1–10.0)
821
(564–1150)
39
(23–60)
5.7
(4.0–7.1)
705
(553–970)
42
(26–57)
6.7
(3.8–9.2)
466
(334–576)
73
(62–80)
No data available
Fig. 1. Lysozyme is up-regulated in CSF from Alzheimer disease patients. A) Lysozyme levels in CSF from ten controls (C) and ten Alzheimer (AD) patients were analyzed using Western
blotting followed by densitometric quantiﬁcation. The blots were cropped. The bars represent themean± SD (**p b 0.01). B) Lysozyme levels in CSF and serum from ten controls (C) and
tenAlzheimer (AD)disease patientswere analyzedusingMeso ScaleDiscovery. The bars represent themean±SEM(**pb 0.01). C) The lysozyme levels inﬁve control (C) samples andﬁve
sampleswith neuronal injury but not Alzheimer's disease (High T-tau)were analyzedusingWestern blotting (the sampleswere appliedwith increasing levels of T-tau as illustrated by the
triangles) followed by densitometric quantiﬁcation. The bars represent the mean ± SD.
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strating that the increase in lysozyme in Alzheimer disease CSF was not
caused by generalized neuronal damage.Fig. 2.Co-localization of lysozyme andAβ1-42 inAlzheimerdisease plaques. A)Representative im
abundant staining of neuritic (arrowhead) and diffuse (asterisk) plaques in human Alzheimer d
presence of lysozyme around a plaque core (arrowheads). C–E & F–H) Double imunoﬂourescen
two proteins (yellow in merge) in the typical cortical plaques in Alzheimer's disease.To study whether lysozyme and Aβ1-42 co-localize in plaques
in Alzheimer disease, immunohistochemistry was performed using
postmortem formalin-ﬁxed and parafﬁn-embedded inferior temporalage of peroxidase immunohistochemistrywith an antibody speciﬁc for lysozyme, showing
isease inferior temporal cortex tissue. B) Immunohistochemistry of lysozyme showing the
ce labeling of the Aβ1-42 (green) and lysozyme (red) demonstrating co-localization of the
127L. Helmfors et al. / Neurobiology of Disease 83 (2015) 122–133cortex tissues from patients with sporadic Alzheimer disease. The stain-
ing pattern of lysozyme resembled the morphology of diffuse and neu-
ritic plaques (Fig. 2A and B). Double-labeling with antibodies against
lysozyme and Aβ1–42 revealed that lysozyme was localized with Aβ1-
42 in diffuse and neuritic plaques, with clumping of lysozyme around
the plaque core (Fig. 2C–H).
In the CSF from patients with Alzheimer's disease there was no cor-
relation between the levels of Aβ1-42 and lysozyme, largely due to the
similar concentrations of Aβ1-42 (310–390 ng/l) in the CSF samples at
this stage of the Alzheimer's disease. In order to explore whether Aβ
could up-regulate the expression and secretion of lysozyme in cell
models, both neuroglioma cells and differentiated human neuroblasto-
ma cells were exposed for 24 h or 24 and48h, respectively, to a subtoxic
concentration of 1 μM oligomeric Aβ1-42. A signiﬁcant increase in both
intracellular lysozyme and secreted lysozyme was detected from the
neuroglioma cells (Fig. 3A–B). In the neuroblastoma cells, secreted lyso-
zyme was not detected in the medium (data not shown) and theFig. 3. Lysozyme is up-regulated in neuroglioma and neuroblastoma cells treatedwith oligomer
for 24 or 48 hwere analyzed usingWestern blot. Densitometric quantiﬁcationswere performed
bars represent themean± SD, n= 3 (*p b 0.05). Blots were cropped. A) Lysozyme levels in neu
roblastoma cells.intracellular level of lysozyme was not changed after 24 h, but was
signiﬁcantly increased after 48 h of Aβ1-42 exposure (Fig. 3C). This
result demonstrates that Aβ can trigger the expression of lysozyme
in cell-based systems and indicates that the increased levels of ly-
sozyme in CSF from Alzheimer disease patients might originate
from gliacells.
3.2. Lysozyme suppresses the toxicity of Aβ in D. melanogaster
On the basis of these clinical results,we developed a novel lysozyme/
Aβ1-42Drosophila line by co-expressing human lysozyme with Aβ1-42
(lysozyme:Aβ) in the CNS using the neuronal-speciﬁc C155-gal4 driver.
Both lysozyme and Aβ1-42 were expressed with a secretion tag to allow
secretion into the extracellular space. A longevity assay was performed
to monitor the toxic effects of the Aβ peptide on ﬂy neurons (Crowther
et al., 2005; Hirth, 2010) and to investigate the impact of lysozyme on
in vivo Aβ toxicity. The median survival time (represented by theic Aβ. Intracellular and secreted levels of lysozyme in cells treatedwith 1 μMoligomeric Aβ
on the scannedWestern blots and normalized to GAPDH levels or Ponceau S staining. The
roglioma H4APPswe cells, B) H4APPswe supernatants and C) differentiated SH-SY5Y neu-
Fig. 4. Protective effect of lysozyme in a Drosophila Alzheimer disease model. A) Survival
trajectories forﬂies expressing Aβ in the CNS in the absence or in the presence of lysozyme
expression compared with control ﬂies. Kaplan–Meier graph showing percent survival vs.
age of ﬂies in days (***p b 0.001). Locomotor assays performedusing iFly: B) velocities and
C) angle of movement recorded over time for Aβ, lysozyme:Aβ and control ﬂies.
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both the control and lysozyme:Aβ ﬂies (Fig. 4A). Thus, co-expressing ly-
sozyme with Aβ resulted in an increased life span of the Aβ ﬂies that
equaled the median survival time of the control ﬂies. To achieve a
more complete picture of ﬂy health, a locomotor assay was performed
using the iFly technique (Jahn et al., 2011) to analyze the velocity and
angle of movement. The average velocity for a healthy young ﬂy is
10 mm/s; as the ﬂy ages, the velocity decreases. Shortly before the
ﬂies die they become immobile and their velocity cannot be recorded;
thus, a cut-off value of 4 mm/s was set as an indication of disability.
The Aβ-expressing ﬂies showed a substantial reduction in their velocity,
reaching the cut-off value of 4mm/s at day 20 comparedwith day 35 for
the control ﬂies (Fig. 4B), when co-expressing lysozyme with Aβ, this
effect was postponed by 6 days and occurred at day 26 (Fig. 4B). The
angle of movement describes the deviation of the ﬂies' path from verti-
cal when they move from the bottom to the top of the vial (Khabirova,
2012). The angle of movement for a healthy young ﬂy is approximately
55°, and this angle increases as the ﬂy ages. A cut-off value of 80°was set
where values above indicate that the mobility functions of the ﬂies
(i.e., orientation and movement direction) are impaired. For the Aβ
ﬂies, the angle of movement diverted from that of healthy control ﬂies
at day 14 when the cut-off value of 80° was reached. However, for the
lysozyme:Aβ ﬂies this day was postponed by 7 days, and the cut-off
value was not reached until day 21. The control ﬂies demonstrated a
normal angle of movement until day 34 (Fig. 4C). The protective effects
of lysozyme in the longevity and locomotor assays of theAβ1-42 express-
ing ﬂies revealed that lysozyme has a pathomechanistic relevant effect
on the reduction of Aβ toxicity.
To investigate the location of Aβ and lysozyme in the ﬂy CNS, sec-
tions of Drosophila brains expressing lysozyme, Aβ or both were co-
stained with antibodies against lysozyme and Aβ1–42. In ﬂies co-
expressing lysozyme and Aβ1-42, the proteins were in close proximity.
This ﬁnding strongly suggests an interaction between these two pro-
teins in the ﬂy CNS (Fig. 5).
The effects of lysozyme on the levels of Aβ1-42 in Drosophila brains
were also analyzed. Soluble and insoluble Aβ1-42 levels were measured
in the Aβ ﬂies with andwithout co-expression of lysozyme at the day of
eclosion (day 0) and 20 days later. For Aβ1-42 expressing ﬂies, the insol-
uble fraction of Aβ1-42 was higher than the soluble fraction both at days
0 and 20 (Fig. 6A, B); indeed these insoluble species accumulated over
time, and a signiﬁcantly higher level was detected at day 20 compared
with day 0 (Fig. 6B). When co-expressing lysozyme and Aβ1-42, the ac-
cumulation of both soluble and insoluble Aβ1-42 in aged ﬂies was signif-
icantly reduced comparedwith ﬂies expressingAβ1-42 alone (Fig. 6A, B).
A reduced level of lysozyme was detected both at day 0 and day 20 in
the lysozyme:Aβ ﬂies compared with the lysozyme alone ﬂies; this dif-
ference was highly signiﬁcant at day 20 (Fig. 6C). These analyses clearly
show that lysozyme and Aβ are able to interact in the ﬂy CNS and that
the presence of lysozyme results in decreased amounts of accumulated
Aβ species in the Aβ1-42 ﬂies.
3.3. Lysozyme binds to and inhibits the Aβ1-42 ﬁbril process and cell death
Next, we studied the in vitro interaction properties between lyso-
zyme and Aβ using FRET steady state ﬂuorescence measurements. The
decrease of donor ﬂuorescence at 520 nm from lysozyme labeled with
Alexa-488 and the increase of acceptor ﬂuorescence at 580 nm from
monomeric Aβ1-42 labeled with TAMRA demonstrated FRET between
the donor and acceptor due to binding of lysozyme with monomeric
Aβ1-42 (Fig. 7A). To investigate the capacity of lysozyme to interact
with ﬁbrillar Aβ, 10 μM of TAMRA-labeled Aβ1-42 was aggregated for
24 h prior to the addition of Alexa-488 –labeled lysozyme (40 μM) for
1 h. Aβwas detected as ﬁbrillar structures, and lysozymewas found as-
sociated with these structures (Fig. 7B).
To investigate whether the binding between lysozyme and Aβ has
any effect on the aggregation kinetics of Aβ, the ﬂuorescence signalfrom thioﬂavin T (ThT) (Brorsson et al., 2010) was followed during
the aggregation of 10 μM Aβ1-42 in the absence and presence of lyso-
zyme. The Aβ aggregation kinetics were substantially slowed down at
a 1:1 ratio between Aβ1-42 and lysozyme; the rate of aggregation (k),
which is a measure of the elongation efﬁciency of ﬁbril formation, was
decreased from 17 min−1 to 5 min−1 and the lag time (tl), which mir-
rors the rate of nucleation events, was prolonged from 4 h to 6 h
(Fig. 8A). The end ThT signal was also greatly reduced from 7800 AU
for Aβ aggregated alone, to 4200 AU in the presence of an equal concen-
tration of lysozyme and to 450 AU in the presence of a four-fold higher
concentration of lysozyme (Fig. 8A). No change in the ThT signal was
detected for lysozyme alone at the two concentrations used (Fig. S1),
having an average signal between 160–180 AU.
Transmission electron microscopy (TEM) images captured at the
24 h time point of the aggregation experiment conﬁrmed ﬁbril forma-
tion by the aggregated Aβ1-42 sample (Fig. 8D) whilst no ﬁbrils could
be detected for the lysozyme samples (Fig. S2). Fibrillar species were
formed in the presence of a 1:1 ratio of theAβ1-42 and lysozyme concen-
trations; these forms were accompanied by smaller aggregated non-
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the aggregated samples were dominated by non-ﬁbrillar structures
(Fig. 8D).
Next, the possible co-localization of Aβ1-42 and lysozyme after 24 h
of aggregation was investigated. When Aβ1-42 was aggregated in the
presence of lysozyme, aggregates were detected by both anti-Aβ and
anti-lysozyme antibodies, thereby demonstrating the co-localization
of Aβ1-42 and lysozyme. The product formed from the 1:1 ratio of Aβ1-
42 and lysozyme appeared as large yellow aggregates where Aβ and ly-
sozyme co-localized; these aggregates were accompanied by some
small spheres of Aβ alone (red) and amorphous species of lysozyme
alone (green) (Fig. 8E). The product formed from the 1:4 ratio of Aβ
and lysozyme appeared as small yellow spheres with almost complete
co-localization (Fig. 8E). Using an ELISA assay that speciﬁcally detects
the aggregated forms of Aβ without detecting monomers (Höltta
et al., 2013), we determined that Aβ1-42 samples aggregated for 24 hFig. 5. Lysozyme and Aβ are localized in close proximity in theDrosophila brain.Drosophila brain
co-stainedwith anti-Aβ (red) and anti-lysozyme (green) antibodies, followedby counterstainin
yellow for the Aβ:lysozyme ﬂies. Sections are from the superior medial protocerebrum and fandemonstrated a high level of aggregated Aβ species, whereas Aβ1-42 ag-
gregated in the presence of lysozyme had signiﬁcantly lower levels of
these aggregated Aβ forms (Fig. 8D). These ﬁndings support the aggre-
gation kinetics results (Fig. 8A, D and E),which suggested that lysozyme
inhibits the ﬁbrillization process of Aβ1-42.
To investigate whether lysozyme could alter the toxic properties of
Aβ, the viability of neuroblastoma cells was monitored, 3 days after ex-
posure to Aβ1-42 aggregated with or without lysozyme, using XTT. Aβ1-
42 was aggregated with or without lysozyme for 6 and 24 h and was
then added to cells. Aβ1-42 was toxic after 6 h of aggregation, causing
cells to shrivel up; however, at 24 h the aggregated Aβ1-42 species
showed no toxicity (Fig. 8C). Moreover, lysozyme protected the cells
against Aβ1-42 toxicity at 6 h. The TEM images in Fig. 8B show that small-
er non-ﬁbrillar species were formedwhen Aβ1-42 was aggregated in the
presence of four-fold more lysozyme for 24 h. No cell toxicity was de-
tected after 24 h of Aβ aggregation with lysozyme, demonstrating thats collected at day 20 fromAβ, lysozyme, Aβ:lysozyme and control ﬂies were sectioned and
gof the cell nucleiwithDAPI (blue). Close proximity betweenAβ and lysozyme is shown in
-shaped body (inset ﬁgure). Scale bars = 50 μm.
Fig. 7. Lysozyme associates with monomeric and ﬁbrillar Aβ. A) Fluorescence intensity of
0.2 μMAlexa-488 labeled lysozyme (donor) in the absence (black line) and in the presence
(red line) of 8 μM TAMRA-labeled monomeric Aβ1-42 (acceptor). The decrease of donor
ﬂuorescence and increase of acceptor ﬂuorescence indicates ﬂuorescence resonance ener-
gy transfer (FRET) between the donor and acceptor due to the association of lysozyme
with monomeric Aβ. B) Representative confocal images of 10 μM Aβ1-42 labeled with
TAMRA that was aggregated for 24 h and then incubated for 1 h with 40 μM lysozyme la-
beled with Alexa Fluor 488. Themerged image of Aβ1-42 and lysozyme ﬂuorescence dem-
onstrates co-localization of the two proteins. Scale bar = 20 μm.
Fig. 6. Lysozyme counteracts the formation of insoluble Aβ species in Drosophila brains.
Levels of Aβ and lysozyme in Drosophila at days 0 and 20 detected by Meso Scale Discov-
ery. A) Amounts of soluble Aβ and B) insoluble Aβ in ﬂies expressing Aβ in the absence or
in thepresence of lysozyme expression comparedwith controlﬂies. C) Amounts of soluble
lysozyme inﬂies expressing lysozyme in the absence and in the presence of Aβ expression
compared with control ﬂies. Bars represent means ± SEM, n = 5 (*p b 0.05; **p b 0.01;
***p b 0.001 and ****p b 0.0001).
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results suggest that the binding of lysozyme to Aβ1-42 decreases the ag-
gregation propensity, and thereby bypasses the route of formation of
toxic Aβ1-42 species.
4. Discussion
Triggering of the innate immune system with the secretion of pro-
and anti-inﬂammatory cytokines is an early event in Alzheimer disease.
Lysozyme is an important player in the innate immune systembut there
has not been any proof of a direct relationship between lysozyme
and Alzheimer disease. However, in a recent microarray study from a
large screen of more than 12,500 genes, the lysozyme gene was identi-
ﬁed to be overexpressed in ﬁve mice models of Alzheimer disease
(Matarin et al., 2015). Two other reports from Luo et al. demonstrate
that lysozyme in vitro binds and prevents the aggregation of Aβ1-40.
The present study further reveals the involvement of lysozyme in
Alzheimer disease where lysozymewas detected at signiﬁcantly higher
levels in CSF from Alzheimer disease patients compared with controls
and was co-localized with Aβ in plaques. We also demonstrate the
physiological relevance of lysozyme using a Drosophila model of Aβ1-
42 toxicity, where lysozyme overexpression prolonged survival andenhanced the activity of the Aβ1-42 ﬂies. At a mechanistic level, in vitro
assays revealed that lysozyme bound to Aβ and inﬂuenced the structure
of aggregated Aβ1-42, thereby reducing the toxicity of Aβ1-42.
Because lysozyme levels were increased in CSF from patients with
Alzheimer disease, we investigated the Alzheimer disease speciﬁcity of
lysozyme using CSF from patients with increased CSF levels of T-tau
but normal Aβ1–42 and P-tau181P values (i.e., patients suffering axonal
damage most likely not caused by Alzheimer disease). Elevated levels
of T-tau is found after acute damage to the brain such as stroke and
subarachnoid hemorrhage, and the levels of these biomarkers correlate
with the severity of the brain damage (Hesse et al., 2000). The lysozyme
levels did not increase with increasing levels of T-tau, which implies
that increased lysozyme levels in the Alzheimer disease CSF is
not secondary to general neurodegeneration. The activation of neuro-
inﬂammatory pathways in the brain is emphasized as amajor risk factor
for the development of Alzheimer disease. Several reports from trans-
genic mice studies indicated that immune activation might prime the
brain for Alzheimer disease pathology, such as Aβ plaques and tau ag-
gregation (Qiao et al., 2001; Sheng et al., 2003; Kitazawa et al., 2005).
If the increased lysozyme levels in CSF from Alzheimer disease patients
are triggered by early immune activation, the detection of lysozyme in
CSF might be useful as a biomarker for Alzheimer disease particularly
in its early preclinical phase. We also showed that lysozyme is closely
associated with cortical amyloid plaques, therefore the physiological
relevance of lysozyme was investigated in a Drosophila model of Aβ1-
42 toxicity. Aβ1-42 expressed in the ﬂy CNS resulted in neurological im-
pairments that manifested as effects on the longevity and locomotor as-
says. The health of Aβ-expressing ﬂies was remarkably increased when
lysozyme was co-expressed with Aβ; the lifespan was extended to that
of normal ﬂies and the locomotor activity was substantially improved.
The level of insoluble Aβ was found to be considerably higher in the
brains of the Aβ1-42 ﬂies compared with the soluble levels of the
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Thus, it is likely that these insoluble Aβ species or intermediate species
formed on the pathway toward insoluble species are cytotoxic and con-
tribute to the reduction in lifespan and locomotor activity observed for
the Aβ1-42 ﬂies. When Aβ was co-expressed with lysozyme, the level
of insoluble Aβ species was reduced in both young and aged ﬂies, indi-
cating that the rescue effects in the lysozyme:Aβ ﬂies are caused by the
capacity of lysozyme to counteract the formation of these insoluble Aβ
species, thereby reducing the formation of toxic Aβ species.
We revealed that lysozyme bound to both monomeric and ﬁbrillar
Aβ1-42; this result is in agreement with recent studies where lysozyme
was demonstrated to bind to monomeric Aβ1-40 (Luo et al., 2013,
2014). Additionally, we detected co-localization between lysozyme
and Aβ in aggregates formed both in vivo and in vitro. Our observation
that lysozyme reduces the aggregation kinetics of Aβ is likely caused
by the binding of lysozyme to monomeric Aβ during the initiation of
the nucleation phase. In turn, this binding results in a change in the
Aβ aggregation process where ﬁbril formation of Aβ is prevented and
the formation of aggregated non-ﬁbrillar species, composed of both ly-
sozyme and Aβ, is promoted. Studies on cells showed that during the
aggregation process of Aβ, cytotoxic aggregated species were formed
at 6 h, whereas in the presence of lysozyme no cytotoxic species were
formed. This demonstrates that when lysozyme binds to monomeric
Aβ, the pool of free monomeric Aβ peptides that can aggregate and
form cytotoxic species is reduced in favor of the formation of non-
toxic, non-ﬁbrillar lysozyme-Aβ species. The formation of these species
is likely to occur via a pathway that differs from the Aβ aggregation
pathway towards ﬁbril formation. Luo et al. recently showed that lyso-
zyme also prevents the toxicity of Aβ1-40 (Luo et al., 2014). The in vivo
step at which lysozyme was able to rescue Aβ cytotoxicity in the ﬂy
CNS is likely to be in line with the in vitro effect of lysozyme on the Aβ
aggregation process. By binding of lysozyme to monomeric Aβ in theFig. 8. Effect of lysozyme on Aβ aggregation and cytotoxicity. A) Aggregation of 10 μMAβ alone
ﬂuorescence curves are shown, n = 3. B) Detection of aggregated Aβ species by ELISA of Aβ ag
entiated SH-SY5Y cells analyzed by XTT after 3 days of exposure to Aβ aggregated at 10 μM fo
medium. The bars represent the mean ± SD, n = 4 (*p b 0.05, **p b 0.01). D) TEM images o
taken at the end of the aggregation experiment in A. Scale bar = 500 nm. E) Fluorescence from
the end of the aggregation experiments in A. Scale bar = 20 μm.ﬂy brain, less Aβ peptides are able to aggregate into cytotoxic species.
Instead, the lysozyme-bound Aβ peptides either participate in the for-
mation of other, presumptively non-toxic, aggregates composed of
both lysozyme and Aβ or are degraded, because the degradation of lyso-
zyme and Aβ seems to be more efﬁcient when the proteins are co-
expressed comparedwith when the proteins are expressed individually
(Kumita et al., 2012).
Little is known about the implications of lysozyme involvement in
Alzheimer disease. One pathological feature of Alzheimer disease is
the failure of the lysosomal clearance mechanisms that manifests as a
severe buildup of lysosomal-related compartments in dystrophic
neurites (Nixon et al., 2005). Our ﬁnding that lysozyme is increased in
CSF fromAlzheimer disease patientsmight represent a cellular compen-
sation for decreased lysosomal function in the Alzheimer disease brain
(Nixon and Yang, 2011) via the up-regulation of lysosomal proteins
such as lysozyme (Gupta et al., 1985). The lysosomal proteins LAMP-1,
LAMP-2 and cathepsin D have previously been reported to be increased
in CSF from Alzheimer disease patients (Schwagerl et al., 1995;
Armstrong et al., 2014). Because neuroinﬂammation is part of the pa-
thology of most lysosomal storage disorders, the up-regulation of lyso-
somal proteins might be a general phenomenon in these disorders. A
functional loss of the lysosomal system may also affect phagocytosis
and recycling in microglial cells, which might in turn lead to microglial
activation and increased secretion of lysozyme. Another possibility is
that the up-regulation of lysozyme might be directly caused by the ac-
cumulation of Aβ in Alzheimer disease patients, because our study dem-
onstrated that exposure of neuroglia cells to Aβ caused up-regulated
expression and secretion of lysozyme. No secretion of lysozymewas de-
tected from neuroblastoma cells, indicating that the origin of lysozyme
in CSF and plaques is astrocytic rather than neuronal.
Our results demonstrating the rescue effects of lysozyme on Aβ tox-
icity establish a potential protective role for lysozyme in Alzheimeror in the presence of 10 μMor 40 μM lysozyme for 24 h probed by ThT. Representative ThT
gregated for 24 h alone or with increasing lysozyme concentrations. C) Viability of differ-
r 6 or 24 h alone or in the presence 40 μM lysozyme and then diluted 1:10 in cell culture
f 10 μM Aβ aggregated alone or in the presence of 10 or 40 μM lysozyme. Images were
the anti-Aβ antibody (red) and anti-lysozyme antibody (green) in samples analyzed at
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cosidase activity also has antioxidant properties via binding to advanced
glycation end products that generate reactive oxidant species (Liu et al.,
2006). An increased expression of lysozyme could also be due to the
modiﬁcation of the glycosylation pattern of proteins in Alzheimer dis-
ease. APP is glycosylated at Asn467 (Pahlsson et al., 1992), and the dele-
tion of Asn467 affects the intracellular sorting of APP (Yazaki et al.,
1996). It was also demonstrated that CSF from Alzheimer disease pa-
tients has increased levels of glycosylated short Aβ fragments (Halim
et al., 2011). However, understandingwhether lysozyme bindsmore ef-
ﬁciently to glycosylated Aβ species or modiﬁes Aβ generation via
changes in glycosylation patterns requires further investigation.
We propose that the increased level of lysozyme in CSF is a protec-
tive response that eventually becomes overwhelmed by Alzheimer dis-
ease pathology. This is supported by the presence of lysozyme in Aβ1-42
plaques in patients with Alzheimer disease. The existence of lysozyme
in mature plaques may be a residual effect of unsuccessful inhibition
of oligomer formation, perhaps due to insufﬁcient lysozyme levels or
the lack of persistence of sufﬁcient levels to achieve this function.
Adding our ﬁndings that lysozyme has an inhibitory effect on Aβ aggre-
gation and cytotoxicity to previous reports that lysozyme has anti-
inﬂammatory and anti-oxidative properties indicates that lysozyme is
an interesting therapeutic target for Alzheimer disease. To investigate
the feasibility of lysozyme as an intervention for Alzheimer disease, ini-
tial mechanistic studies should be performed in an APPmousemodel to
pinpoint the optimal time for intervention, any side effects fromaltering
lysozyme expression aswell as toxicity studies for themethod of choice
for achieving lysozyme overexpression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2015.08.024.
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